Eli M. Wallace - Aug 11, 2025 Form 3 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Role: Chief Executive Officer, Director
Signature: /s/ Aaron Chan, Attorney-in-Fact
Stock symbol: BBOT
Transactions as of: Aug 11, 2025
Transactions value $: $0
Form type: 3
Date filed: 8/18/2025, 05:10 PM
Next filing: Aug 28, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wallace Eli M.	Chief Executive Officer, Director	BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO	/s/ Aaron Chan, Attorney-in-Fact	2025-08-18	0001776352

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BBOT	Stock Option (Right to Buy)							Aug 11, 2025	Common Stock	621K	$4.17	Direct	F1
holding	BBOT	Stock Option (Right to Buy)							Aug 11, 2025	Common Stock	37.2K	$7.88	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of May 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2	1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney